UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl)
Focal therapy
Changing the landscape of prostate cancer treatments
Scheltema, M.J.V.
Publication date
2018
Document Version
Other version
License
Other
Link to publication
Citation for published version (APA):
Scheltema, M. J. V. (2018). Focal therapy: Changing the landscape of prostate cancer
treatments.
General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).
Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
12
AUTHOR CONTRIBUTIONS
AMC GRADUATE SCHOOL PHD PORTFOLIO
LIST OF PUBLICATIONS
CURRICULUM VITAE
ACKNOWLEDGEMENTS/DANKWOORD
S
AUTHOR CONTRIBUTIONS
Author’s initials
MJ Scheltema MS W van den Bos WB TM de Reijke TR
DM de Bruin DB AW Postema AP JJ de la Rosette JR
MP Laguna MP M Böhm MB W Delprado WD
I Gielchinsky IG AR Siriwardana AS R Shnier RS
PD Stricker PS M Buijs MU MR Engelbrecht ME
H Wijkstra HW AM Kalsbeek AK JE Thompson JT
F Ting FT AM Haynes AH TV Nguyen TN
PJ van Leeuwen PL Experts panel:
KJ Tay, J Feller, JJ Futterer, AK George, RT Gupta, F Kahmann, C Kastner, S Natarajan, S Rais-Bahrami, AR Rantinehad, G Salomon, N Stone, R van Velthoven, R Villani, A Villers, J Walz, TJ
Polascik EP
Chapter 2
Utilization of Multiparametric Prostate Magnetic Resonance Imaging in Clinical Practice and Focal Therapy: report from a Delphi consensus project.
Scheltema MJ, Tay KJ, Postema AW, de Bruin DM, Feller J, Futterer JJ, George AK, Gupta RT, Kahmann F, Kastner C, Laguna MP, Natarajan S, Rais-Bahrami S, Rastinehad AR, de Reijke TM, Salomon G, Stone N, van Velthoven R, Villani R, Villers A, Walz J, Polascik TJ, de la Rosette JJ
Conception and design: MS, AP, EP, DB, TR and JR Data/literature acquisition: MS and AP
Data/literature analysis and interpretation: MS, AP, EP and JR
Statistical analysis: MS
Drafting the manuscript: MS, AP, EP, DB and JR Critical revision of the manuscript: All authors
Supervision: EP, DB and JR
Chapter 3
Preliminary Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Focal Therapy with Irreversible Electroporation.
Scheltema MJ, Chang JI, van den Bos W, Böhm M, Delprado W, Gielchinsky I, de Reijke TM, de la Rosette JJ, Siriwardana AR, Shnier R, Stricker PD
Conception and design: MS, WB and PS Data/literature acquisition: MS, JC, WB, MB and PS Data/literature analysis and interpretation: MS
Statistical analysis: MS
Drafting the manuscript: MS
Critical revision of the manuscript: All authors
Supervision: TR, JR and PS
CHAPTER 4
Irreversible electroporation for the treatment of localized prostate cancer: a summary of imaging findings and treatment feedback.
Scheltema MJ, Postema AW, de Bruin DM, Buijs M, Engelbrecht MR, Laguna MP, Wijkstra H, de Reijke TM, de la Rosette JJ
Conception and design: MS, AP and DB
Data acquisition: MS and AP
Data analysis and interpretation: MS, AP and DB
Statistical analysis: MS and DB
Drafting the manuscript: MS, AP and MU Critical revision of the manuscript: All authors
Supervision: HW, TR and JR
Chapter 5
Focal irreversible electroporation as primary treatment for localized prostate cancer.
van den Bos W, Scheltema MJ, Siriwardana AR, Kalsbeek AM, Thompson JE, Ting F, Böhm M, Haynes AM, Shnier R, Delprado W, Stricker PD
Conception and design: MS, WB, AS and PS Data/literature acquisition: MS, WB, AS, MB and PS Data analysis and interpretation: MS, WB, AK and JT
Statistical analysis: MS, WB and AK
S
Critical revision of the manuscript: All authorsSupervision: PS
Chapter 6
Impact on Genito-Urinary Function and Quality of Life following Focal Irreversible Electroporation of Different Prostate Segments
Scheltema MJ, Chang JI, van den Bos W, Gielchinsky I, Nguyen TV, de Reijke TM, Siriwardana AR, Böhm M, de la Rosette JJ, Stricker PD
Conception and design: MS, WB and PS Data/literature acquisition: MS, WB, AS, MB and PS Data analysis and interpretation: MS
Statistical analysis: MS and TN
Drafting the manuscript: MS, JC, IG and MB Critical revision of the manuscript: All authors Supervision: PS
Chapter 7
Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer.
Scheltema MJ, van den Bos W, Siriwardana AR, Kalsbeek AM, Thompson JE, Ting F, Böhm M, Haynes AM, Shnier R, Delprado W, Stricker PD
Conception and design: MS, WB, AS and PS Data/literature acquisition: MS, WB, AS, MB and PS Data analysis and interpretation: MS, WB, and AK
Statistical analysis: MS
Drafting the manuscript: MS, WB, AS, AK and MB Critical revision of the manuscript: All authors
Supervision: PS
Chapter 8
Pair-matched Patient-reported Quality of Life following Focal Irreversible Electroporation versus Robot-Assisted Radical Prostatectomy; an alternative approach to study outcomes of a new prostate cancer treatment
Scheltema MJ, Chang JI, Böhm M, van den Bos W, Gielchinsky I, Kalsbeek AM, van Leeuwen PJ, Nguyen TV, de Reijke TM, Siriwardana AR, Thompson JE, de la Rosette JJ, Stricker PD
Conception and design: MS and PS
Data/literature acquisition: MS, MB, JC and PS Data analysis and interpretation: MS
Statistical analysis: MS and TN
Drafting the manuscript: MS, JC, IG and MB Critical revision of the manuscript: All authors Supervision: PS
Chapter 9
Focal vs Extended Ablation in Localized Prostate Cancer with Irreversible Electroporation; A Multi-Center Randomized Controlled Trial.
Scheltema MJ, van den Bos W, de Bruin DM, Wijkstra H, Laguna MP, de Reijke TM, de la Rosette JJ
Conception and design: WB, DB, TR, HW and JR Data/literature acquisition: MS and WB
Data/literature analysis and interpretation: MS and WB
Statistical analysis: WB and DB
Drafting the manuscript: MS
Critical revision of the manuscript: All authors Supervision: JR
S
PORTFOLIO
PhD period: 2016 - 2017
Locations: Department of Urology, AMC University Hospital, Amsterdam Garvan Institute of Medical Sciences, University of New South Wales, Sydney, Australia
St. Vincent’s Private Hospital, Sydney, Australia PhD supervisor: prof. dr. JJMCH de la Rosette, prof. dr. MP Laguna Pes Co-supervisor: dr. DM de Bruin, dr. TM de Reijke
PhD training
Graduate School Courses Year ECTS
Entrepreneurship in Health and Life Sciences 2016 1.1
Practical Biostatistics 2016 1.1
Basic Course on Legislation and Organization of Animal Trials 2016 2.0
Clinical Data Management 2016 0.2
Basic Course in Legislation and Organization for Clinical Researchers 2016 0.9
Oral, poster and video presentations Year ECTS
Pair-matched Patient-reported Quality of Life following Focal Irreversible Electroporation versus Robot-Assisted Radical Prostatectomy
37th Congress of the Societe Internationale d’Urologie (SIU), Lissabon, Portugal
2017 0.5
Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging Following Prostate Cancer Focal Therapy with Irreversible Electroporation.
Genito-Urinary Function and Quality of Life after Focal Irreversible Electroporation of Different Prostate Segments.
87th Annual Meeting American Urological Association (western section), Vancouver, Canada.
2017 1
Irreversible Electroporation for localized prostate cancer - Where it started and where to go
Irreversible Electroporation for small renal masses
1st Masterclass Focal Therapy for localized prostate cancer, Mexico City, Mexico
2017 1
Focal irreversible electroporation as primary and salvage treatment for prostate cancer. Superior biochemical recurrence and long-term quality of life outcomes are achievable with robotic radical prostatectomy after a long learning curve – updated analysis of a prospective single-surgeon cohort of 2,206 consecutive cases
5th Global Congress on Prostate Cancer (PROSCA), Lissabon, Portugal.
2017 1
Utilization of multiparametric prostate MRI in Clinical Practice and Focal Therapy. Oral presentation
9th International Symposium on Focal Therapy & Imaging, Durham, USA
2016 0.5
Update randomized controlled trial focal vs extended IRE in localized Prostate Cancer and New Protocol
Salvage IRE after radio-recurrent Prostate Cancer
3th irreversible electroporation meeting, AMC, Netherlands.
(Inter)national conferences, seminars, masterclasses Year ECTS
37th Congress of the Societe Internationale d’Urologie (SIU), Lissabon, Portugal 2017 0.25 87th Annual Meeting American Urological Association (western section),
Vancouver, Canada.
2017 0.25 1st Masterclass Focal Therapy for localized prostate cancer, Mexico City, Mexico 2017 0.25 5th Global Congress on Prostate Cancer (PROSCA), Lissabon, Portugal. 2017 0.25 34th World Congress of Endourology, Cape Town, South Africa 2017 0.25 2nd Amsterdam Intervention Oncology Summit (AMIOS) 2016 0.25
Clinical Training MRI-US Fusion Guided Prostate Biopsies, AMC 2016 0.25
9th International Symposium on Focal Therapy & Imaging, Durham, USA 2016 0.25
Urology seminars AMC/VUmc 2016/2017 0.25
Masterclass Synchronizing ADT for Metastasized Prostate Cancer, Amsterdam 2016 0.1
Annual Meeting, Dutch Association Urology 2016/2017 0.5
Grants Year
PhD grant: Cure for Cancer 2016/2017
Fellowship grant: Australian Prostate Cancer Research Centre – New South Wales 2017 Epigenetic tissue testing to diagnose prostate cancer 2017
S
PUBLICATIONS
Superior Biochemical Recurrence and Long-term Quality-of-life Outcomes Are Achievable with Robotic Radical Prostatectomy After a Long Learning Curve—Updated Analysis of a Prospective Single-surgeon Cohort of 2206 Consecutive Cases
Thompson JE, Egger S, Böhm M, Siriwardana AR, Haynes AM, Matthews J, Scheltema
MJ, Stricker PD.
Eur Urol 2018; in print. Doi:10.1016/j.eururo.2017.11.035
Predictive value of 68Ga-PSMA PET and mpMRI for the presence of clinically significant prostate cancers on histopathology. Does 68Ga-PSMA PET add value to mpMRI?
Chang JI, Scheltema MJ, Stricker PD, van Leeuwen PJ, Nguyen QA, Ho S, Delprado W, Lee J, Thompson BD, Cusick T, Spriensma AS, Siriwardana AR, GielchinskyI, Shnier R, Yuen C, Kooner R, Brenner P, O’Neill G, Louise Emmett
J Nucl Med. 2018; submitted
Numerical Simulation Modeling of the Irreversible Electroporation Treatment Zone for Focal Therapy of Prostate Cancer, correlation with whole-mount pathology.
Scheltema MJ, O’Brien TJ, Agnass P, van den Bos W, Davalos RV, van der Geld CW, van
Gemert MJ, de la Rosette JJ, Laguna MP, Neal RE , de Reijke TM, Stricker PD, de Bruin DM, Arena CB.
Prostate; submitted
Pair-matched Patient-reported Quality of Life following Focal Irreversible Electroporation versus Robot-Assisted Radical Prostatectomy; an alternative approach to study outcomes of a new prostate cancer treatment.
Scheltema MJ, Chang JI, Böhm M, van den Bos W*, Gielchinsky I, Kalsbeek AM, van
Leeuwen PJ, Nguyen TV, de Reijke TM, Siriwardana AR, Thompson JE, de la Rosette JJ, Stricker PD.
World Journal of Urology 2018; epub ahead of print doi:10.1007/s00345-018-2281-z
Impact on Genito-Urinary Function and Quality of Life after Focal Irreversible Electroporation of Different Prostate Segments.
Scheltema MJ, Chang JI, van den Bos W, Gielchinsky I, Nguyen TV, de Reijke TM,
Siriwardana AR, Böhm M, de la Rosette JJ, Stricker PD.
Preliminary Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Focal Therapy with Irreversible Electroporation.
Scheltema MJ, Chang JI, van den Bos W, Böhm M, Delprado W, Gielchinsky I, de Reijke
TM, de la Rosette JJ, Siriwardana AR, Shnier R, Stricker PD.
Eur Urol Focus. 2017 Nov 1. pii: S2405-4569(17)30244-4. doi:10.1016/j. euf.2017.10.007
Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer.
Scheltema MJ*, van den Bos W*, Siriwardana AR, Kalsbeek AMF, Thompson JE, Ting F,
Böhm M, Haynes AM, Shnier R, Delprado W, Stricker PD.
BJU Int. 2017 Nov;120 Suppl 3:51-58. doi: 10.1111/bju.13991. Epub 2017 Sep 19.Mar 2017
Irreversible electroporation for the treatment of localized prostate cancer: a summary of imaging findings and treatment feedback.
Scheltema MJ, Postema AW, de Bruin DM, Buijs M, Engelbrecht MR, Laguna MP, Wijkstra H,
de Reijke TM, de la Rosette JJMCH. Diagn Interv Radiol. 2017 Sep-Oct;23(5):365-370.
doi: 10.5152/dir.2017.16608.
Focal irreversible electroporation as primary treatment for localized prostate cancer. van den Bos W*, Scheltema MJ*, Siriwardana AR, Kalsbeek AMF, Thompson JE, Ting F, Böhm M, Haynes AM, Shnier R, Delprado W, Stricker PD. BJU Int. 2017 Aug 10. doi:
10.1111/bju.13983.[epub ahead of print]
Treatment outcomes from 68GaPSMA PET CT informed salvage radiation treatment in men with rising PSA following radical prostatectomy: Prognostic value of a negative PSMA PET.
Emmett L, Van Leeuwen P, Nandurkar R, Scheltema MJ, Cusick T, Hruby G, Kneebone A, Eade T, Fogarty G, Jagavkar R, Nguyen Q, Ho B, Joshua AM, Stricker P. J Nucl Med. 2017
Jul 26. pii: jnumed.117.196683. doi: 10.2967/jnumed.117.196683.
The prostate cancer detection rates of CEUS-targeted versus MRI-targeted versus systematic TRUS-guided biopsies in biopsy-naïve men: a prospective, comparative clinical trial using the same patients.
Postema AW, Scheltema MJ, Mannaerts CK, Van Sloun RJ, Idzenga T, Mischi M, Engelbrecht MR, De la Rosette JJ, Wijkstra H. BMC Urol. 2017 Apr 5;17(1):27. doi:
S
Patient selection for prostate focal therapy in the era of active surveillance: anInternational Delphi Consensus Project.
Tay KJ, Scheltema MJ, Ahmed HU, Barret E, Coleman JA, Dominguez-Escrig J, Ghai S, Huang J, Jones JS, Klotz LH, Robertson CN, Sanchez-Salas R, Scionti S, Sivaraman A, de la Rosette J, Polascik TJ. Prostate Cancer Prostatic Dis. 2017 Sep;20(3):294-299. doi:
10.1038/pcan.2017.8. Epub 2017 Mar 28.
Irreversible Electroporation for the Ablation of Renal Cell Carcinoma: A Prospective, Human, In Vivo Study Protocol (IDEAL Phase 2b).
Buijs M, van Lienden KP, Wagstaff PG, Scheltema MJ, de Bruin DM, Zondervan PJ, van Delden OM, van Leeuwen TG, de la Rosette JJ, Laguna MP. JMIR Res Protoc. 2017 Feb
16;6(2):e21. doi: 10.2196/resprot.6725
Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project.
Scheltema MJ, Tay KJ, Postema AW, de Bruin DM, Feller J, Futterer JJ, George AK, Gupta
RT, Kahmann F, Kastner C, Laguna MP, Natarajan S, Rais-Bahrami S, Rastinehad AR, de Reijke TM, Salomon G, Stone N, van Velthoven R, Villani R, Villers A, Walz J, Polascik TJ, de la Rosette JJMCH. World J Urol. 2017 May;35(5):695-701. doi:
10.1007/s00345-016-1932-1. Epub 2016 Sep 16.
Surveillance following Focal Therapy interventions.
Postema AW, Catellani M, Scheltema MJ, van den Bos W, de la Rosette JJ. Arch Esp Urol.
2016 Jul;69(6):364-74
Irreversible electroporation, a new modality in Focal Therapy for prostate cancer.
Scheltema MJ, van den Bos W, Wagstaff PG, Postema AW, de Bruin DM, Laguna Pes MP,
de la Rosette JJ. Arch Esp Urol. 2016 Jul;69(6):337-44.
Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial.
Scheltema MJ*, van den Bos W*, de Bruin DM, Wijkstra H, Laguna MP, de Reijke TM, de la
Rosette JJ. BMC Cancer. 2016 May 5;16:299. doi: 10.1186/s12885-016-2332-z.
Clinical relevance of the bile acid receptor TGR5 in metabolism.
van Nierop FS, Scheltema MJ, Eggink HM, Pols TW, Sonne DP, Knop FK, Soeters MR.
Lancet Diabetes Endocrinol. 2017 Mar;5(3):224-233. doi: 10.1016/S2213-8587(16)30155-3. Epub 2016 Sep 14.
Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion.
Hansen M, Scheltema MJ, Sonne DP, Hansen JS, Sperling M, Rehfeld JF, Holst JJ, Vilsbøll T, Knop FK. Diabetes Obes Metab. 2016 Jun;18(6):571-80. doi: 10.1111/dom.12648.
Epub 2016 Mar 22.
Rare Diseases as Research Model.
Scheltema MJ, Soeters MR, Linthorst GE. Ned Tijdschr Geneeskd. 2012;156(17):A4223.
BOOK CHAPTERS
Irreversible Electroporation of Prostate Tumors.
Scheltema MJ, de la Rosette JJMCH. Irreversible Electroporation in Clinical Practice,
Springer 2017. In print.
Positioning Focal Therapy from Consensus to Guidelines.
Scheltema MJ, Hentschel AE, de la Rosette JJ. Imaging and Focal Therapy of Early
Prostate Cancer. Current Clinical Urology, Springer 2017
PRESENTATIONS
37th Congress of the Societe Internationale d’Urologie (SIU), Lissabon, Portugal
Pair-matched Patient-reported Quality of Life following Focal Irreversible Electroporation versus Robot-Assisted Radical Prostatectomy
87th Annual Meeting American Urological Association(western section), Vancouver, Canada.
- Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging Following Prostate Cancer Focal Therapy with Irreversible Electroporation.
- Genito-Urinary Function and Quality of Life after Focal Irreversible Electroporation of Different Prostate Segments.
5th Global Congress on Prostate Cancer (PROSCA), Lissabon, Portugal.
- Focal irreversible electroporation as primary and salvage treatment for prostate cancer. - Superior biochemical recurrence and quality of life outcomes are achievable with
robotic radical prostatectomy versus open radical prostatectomy - update of a prospective single - surgeon study of 2,206 consecutive cases.
S
10th International Symposium on Focal Therapy & Imaging, Noordwijk, Netherlands.Irreversible Electroporation - Current Status in Primary and Radio-recurrent Prostate Cancer.
9th International Symposium on Focal Therapy & Imaging, Durham, USA.
Utilization of Multiparametric Prostate Magnetic Resonance Imaging in Clinical Practice and Focal Therapy: report from a Delphi consensus project.
Falk Symposium 194 XXIII International Bile Acid Meeting: Bile Acids as Signal Integrators and Metabolic Modulators, Freiburg, Germany
Post-meal Bile Acid profiles and Metabolic Response in Cerebrotendinous Xanthomatosis Patients.
74th Scientific Sessions of the ADA, San Francisco, Calfornia, USA
Effect of Chenodeoxycholic Acid and Colesevelam on Glucose Metabolism in Patients with Type 2 Diabetes and Healthy Control Subjects.
50th Annual Meeting of the EASD, Vienna, Austria
Effect of Chenodeoxycholic Acid and Colesevelam on Glucose Metabolism in Patients with Type 2 Diabetes and Healthy Control Subjects.
S
CURRICULUM VITAE
Matthijs Scheltema was born on July 17th 1990 in Soest, the Netherlands. In 2009 he graduated from the Baarnsch Lyceum and continued his education at the University of Amsterdam by studying medicine. During medical school he developed his interest for medical research by studying the physiological effects of bile acids, both in Amsterdam and during his 6-month research rotation in Copenhagen, Denmark. He did his senior clerkship at the department of urology of the Academic Medical Center Amsterdam with a keen interest to become a urologist. In December 2015 he graduated with distinction from medical school after which he continued his career with a combined clinical and research appointment at the Department of Urology of the Academic Medical Center. He completed his PhD under the supervision of prof. dr. J.J. de la Rosette, during which he coordinated and conducted multiple studies concerning focal therapy and imaging for localized prostate cancer. During his PhD he spent 5 months in Sydney, Australia, after obtaining a fellowship grant from the Australian Prostate Cancer Research Centre Australia. In this research fellowship, under the supervision of professor Phillip D. Stricker, he was appointed to coordinate the clinical research department on focal therapy for prostate cancer. His PhD project and research fellowship resulted in the writing of this thesis in 2017. Matthijs is currently appointed as surgical resident in training at the Flevoziekenhuis in Almere, as part of his urology training at the medical center of the Vrije Universiteit Amsterdam.
S
ACKNOWLEDGEMENTS/DANKWOORD
Middels deze sectie wil ik graag iedereen bedanken die heeft bijgedragen aan de totstandkoming van dit proefschrift; onwijs bedankt! Ik mag mij gelukkig prijzen om zowel in Nederland als Australië te hebben gewerkt, in de kliniek alsmede gekluisterd aan de computer. Deze combinatie van werken, leuke collega’s en inspirerende stof hebben mij enorm veel energie gegeven de afgelopen jaren. Graag wil ik een aantal personen specifiek bedanken die een belangrijke rol hebben vervuld in mijn promotieonderzoek. Allereerst wil ik graag mijn beide promotoren, prof. de la Rosette en prof. Laguna, bedanken voor het gestelde vertrouwen de afgelopen jaren. Door dit vertrouwen heb ik mijn onderzoeksprojecten echt naar eigen hand kunnen zetten, een belangrijke voorwaarde voor de opleiding tot onderzoeker. Ik heb een groot aantal mogelijkheden van u gekregen, waarvoor ik erg dankbaar ben.
Geachte dr. de Reijke, beste Theo, ik wil je graag bedanken voor alle begeleiding in zowel de kliniek als bij mijn onderzoek. Ik ben heel blij dat ik als beginnend arts en onderzoeker een aantal jaar onder jouw supervisie heb mogen werken; ik heb veel van je geleerd. Tevens wil ik je bedanken voor het trouw en grondig doornemen van al mijn manuscripten.
Beste Martijn, het was heel verfrissend en relaxed om jou als begeleider te hebben. Ik waardeer je biomedische achtergrond evenals je voorliefde voor het goede leven. Ik heb nog nooit zulke erge meat sweats gehad als na de steaks in North Carolina. Dear prof. Stricker, dear Phil, although you did not have an official position as supervisor in my PhD project, you taught me a lot about prostate cancer and focal therapy. I really enjoyed my time at St. Vincent’s and respect your work and clinic, how you combine it with your personal life and the opportunities you provide to others. I hope that we will be able to work together again in the future.
Geachte leescommissie, geachte heren. Dank voor het grondig en kritisch doornemen van mijn proefschrift. Ik waardeer de tijd en energie die u hiervoor heeft vrijgemaakt en kijk uit naar mijn verdediging.
Paranimfjes, lieve Nienke en Mara. Tegenover een mannelijke leescommissie is wat vrouwelijke ondersteuning aan mijn zijde erg prettig. Nien, het was leuk om zo samen als familie de promotietijd te doorlopen, ik hoop snel jouw promotie te mogen aanschouwen. Mara, mate, jij was het juiste tegenwicht van alle rust, reinheid en regelmaat die het werk van ons vroeg.
Beste uro en biomedical onderzoekers; dank voor alle koffietjes, 2e koffietjes, 3e koffietjes,
lunch, cola-breaks, snoepgoed, gratis eten, bier en lol die we de afgelopen jaren hebben gehad. Het zijn juist die dingen die je als onderzoeker gaande houden en maakten dat ik met veel plezier naar mijn werk ging. Arnie en Chrissie, prostate boys for life.
Dear Garvan peeps, it was lovely to work with you guys. We were able to accomplish a lot together in the months that I was working at the Garvan. But most of all, I really enjoyed my position at the Garvan due to all the fantastic coffee, farewell beers, Aussie rules footie and lunches. I hope that we will work together again in the near future. Beste arts-assistenten en stafleden van de urologie, dank voor de leerzame jaren op het AMC. Ik ben blij dat ik een aantal jaar met jullie heb mogen samenwerken. Nogmaals dank voor alle medewerking bij mijn promotieonderzoek. Hetzelfde geldt voor alle ondersteunende staf van de urologie, alle (poli)verpleegkundigen en collega’s uit andere disciplines.
Lieve Pap, Mam, Nienke en Eva, dank voor jullie onvoorwaardelijke hulp en steun. Ik bewonder jullie vermogen om je te interesseren in al mijn prostaatpraat en prijs me een zeer gelukkig man om met jullie het leven te delen.
